← 홈

CGT

73개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 73개
CGTBiologicstaleNovartis PharmaceuticalsPhase 2

Bridging Therapy (Bridging Therapy)

Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 32.1%임상시험 58상태 DISCONTINUED
CGTBiologicstaleHebei Senlang Biotechnology Inc…Preclinical

CD19+CD22 CAR-T (CD19+CD22 CAR-T)

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5
임상시험 53상태 ACTIVE
CGTBiologicstaleCRISPR Therapeutics AGPhase 2

CD19-directed CAR-T cells (CD19-directed CAR-T cells)

B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 25%임상시험 53상태 ACTIVE
CGTBiologicstaleSecuraBio-deliveringPhase 3

Duvelisib (Duvelisib)

Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma · FRα

#FR#CGT#Phase3#세포유전치료#CAR-T+5
효능 ORR 82%임상시험 45상태 RECRUITING
CGTBiologicstaleBristol Myers Squibbvedotin plus bendamustine a…Phase 1

JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) 2-dose schedule, lisocabtagene maraleucel)

Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 80.5%임상시험 34상태 ACTIVE
CGTBiologicstaleCelgenePhase 3

JCAR017 (JCAR017)

Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse · Precursor Cell Lymphoblastic Leukemia-Ly

#PrecursorCellLymphoblasticLeukem#CGT#Phase3#세포유전치료#CAR-T+4
효능 ORR 92.9%임상시험 20상태 ACTIVE
CGTBiologicstaleMiltenyi Biotec, Inc.Phase 1

Autologous CAR19 T lymphocytes (Autologous CAR19 T lymphocytes)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 77.3%임상시험 7상태 RECRUITING
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR011 (C-CAR011)

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

anti-CD5 CAR T cells (anti-CD5 CAR T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE
CGTBiologicstaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (CD19-CAR-DNT cells)

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 5상태 ACTIVE
CGTBiologicstaleGuangdong Ruishun Biotech Co., …Phase 1

CD19-CAR-DNT cells (RJMty19, RJMty19 (CD19-CAR-DNT cells))

B-cell Non-Hodgkin's Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 5상태 RECRUITING
CGTBiologicstaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

Lymphoma; Lymphoma, Non-Hodgkin · CD30

#CD30#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstaleJuno Therapeutics, Inc., a Bris…Phase 1

Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes)

Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent B-Cell Non-Hodgkin Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 1%임상시험 2상태 DISCONTINUED
CGTBiologicstaleTimmune Biotech Inc.Phase 1

CD19-TriCAR-T/SILK (CD19-TriCAR-T/SILK)

Non-Hodgkin Lymphoma of Intestine; Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 ACTIVE
CGTBiologicstaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 94%임상시험 2상태 ACTIVE
CGTBiologicstaleCity of Hope Medical CenterPhase 1

autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells)

Adult Grade III Lymphomatoid Granulomatosis; Cutaneous B-cell Non-Hodgkin Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 2상태 RECRUITING
CGTBiologicstaleNanjing IASO Biotechnology Co.,…Preclinical

chimeric antigen receptor gene modified T cells (chimeric antigen receptor gene modified T cells)

Acute Lymphocytic Leukemia; Lymphoma,Non-Hodgkin · CD30

#CD30#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 92.9%임상시험 2상태 RECRUITING
CGTBiologicstaleBaylor College of MedicinePhase 1

Allogeneic CD5.CAR/28zeta CAR T cells (Allogeneic CD5.CAR/28zeta CAR T cells)

T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Lymphoma

#T-cellAcuteLymphoblasticLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 94%임상시험 1상태 ACTIVE
CGTBiologicstaleMayo ClinicPhase 1

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 (Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563)

Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING

1 / 4 페이지

← 이전다음 →